AriBio - About the company
AriBio is a series B company based in Seongnam-si (South Korea), founded in 2010. It operates as a Developer of a range of therapeutics for different kinds of diseases. AriBio has raised $27.5M in funding.
Company Details
AriBio is developing a range of therapeutics for different kinds of diseases. The company has developed small molecule-based drugs, stem cells, and immunotherapeutic drugs for the treatment of diseases like infectious diseases, neurodegenerative diseases, diabetic complications, etc.
- Website
- www.aribio.com/
- Social
- Phone Number
- +82 **********
Key Metrics
Founded Year
2010
Location
Seongnam-si, South Korea
Stage
Series B
Total Funding
$27.5M in 1 round
Latest Funding Round
Investors
Employee Count
42 as on May 31, 2026
Sign up to download AriBio's company profile
AriBio's funding and investors
AriBio has raised a total funding of $27.5M over 1 round. Its latest funding round was a Series B round on Jul 03, 2026 for $*****. 1 investor participated in its latest round. AriBio has 1 institutional investor.
Here is the list of recent funding rounds of AriBio:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jul 03, 2026 | 9729901 | Series B | 6482883 | 1089349 | 3537441 | 6399518 |
Access funding benchmarks and valuations. Sign up today!View details of AriBio's funding rounds and investors
AriBio's founders and board of directors
Founder? Claim ProfileAriBio's employee count trend
AriBio has 42 employees as of May 26. Here is AriBio's employee count trend over the years:
Uncover AriBio's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
AriBio's Investments and acquisitions
AriBio has made no investments or acquisitions yet.
Reports related to AriBio
Here is the latest report on AriBio's geography:
News related to AriBio
Filter this listMedia has covered AriBio for a total of 7 events in the last 1 year, 3 of them have been about company updates and 1 about partnerships.
•
•
•
Aribio Decides to Issue Convertible Bonds Worth 2.8 Billion KRWDigitalToday•May 04, 2026•AriBio, CHA Biotech
•
Aribio Signs 630 Billion Won Dementia Drug Licensing Deal with Fosun PharmaBusinesskorea•Jan 06, 2026•AriBio, Fosun Pharmaceutical
•
AriBio Selected for UK Government's Vascular Dementia Treatment ProjectBusinesskorea•Nov 14, 2025•AriBio
•
AriBio Signs Exclusive Licensing Deal with Fosun Pharma for Alzheimer’s Drug in ChinaBusinesskorea•Jul 30, 2025•AriBio, Fosun Pharmaceutical
•
AriBio licenses Alzheimer’s drug to Arcera in $600 M dealBioSpectrum Asia•Jun 10, 2025•AriBio, Arcera
•
AriBio & Arcera sign deal for Alzheimer’s drug AR1001 commercializationGlobeNewswire•Jun 10, 2025•Arcera, AriBio
•
Financial Supervisory Service Takes on the Role of Verifying Merger RratiosBusinesskorea•Jan 02, 2025•AriBio
•
Neurophet, AriBio Partner to Develop a Next-Gen Platform for Alzheimer’s DiagnosisContract Pharma•Oct 15, 2024•NEUROPHET, AriBio
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about AriBio
Explore our recently published companies
- Valor Gold - Canada based, 2025 founded, Unfunded company
- Flora-Et-Ars - Unfunded company
- XenovaCore - London based, 2020 founded, Unfunded company
- C And C Nutra - Ambala based, Unfunded company
- Lumos LEDs - Pune based, 2017 founded, Unfunded company
- Oushvaa - India based, 2026 founded, Unfunded company
